SAB BIOTHERAPEUTICS INC
SABSNASDAQ🏆 #2613 by market capUS Equity
$336.01▼ $18.41 (−5.48%)
Simulated price1h—
24h▼ 5.5%
7d—
14d—
30d—
1y—
🏦Market Cap
$342M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
260.0x
Expensive
Otter Score
47
Weak
No chart data available for SABS.
Trading Snapshot
- Day Range
- $332.21 – $341.94
- 52-Week Range
- $1.85 – $5.15
- Volume
- $4.58B
- Avg Volume
- $3.19B
- Shares Outstanding
- 76.5M
- Next Earnings
- Sep 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $300,941
- P/E Ratio
- 25.9
- P/S Ratio
- 260.0x
- EPS (TTM)
- $-1.42
- Dividend Yield
- —
Why Investors Own SABS
- ✓High-growth profile — revenue up -8.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 19% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$1M▼ −8.9% YoY
Gross Margin (TTM)
45.3%▲ +3.8% YoY
Operating Income (TTM)
$188,165▼ −8.9% YoY
Free Cash Flow (TTM)
$248,694▼ −8.9% YoY
About SAB BIOTHERAPEUTICS INC
A company profile for SAB BIOTHERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
47/100
Analyst Price Target
ⓘAverage Target
$373.08
▲ +11.0% Upside
High Target$456.22
Low Target$289.97
Based on 39 analysts
Latest News & Updates
🚀
CNBC·2h ago
SAB BIOTHERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift SABS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
SAB BIOTHERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.